




RealRate

# PHARMACEUTICAL 2021

Merus N.V.  
Rank 197 of 409

# Merus



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



RealRate

# PHARMACEUTICAL 2021

Merus N.V.  
Rank 197 of 409

# Merus

The relative strengths and weaknesses of Merus N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merus N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Merus N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is -122%, being 233% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	217,993
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,746
Liabilities, Non-Current	2,521
Other Assets	9,109
Other Compr. Net Income	7,485
Other Expenses	503
Other Liabilities	79,687
Other Net Income	-9,132
Property and Equipment	4,115
Research and Development	70,040
Revenues	29,943
Selling, General and Administrative Expense	35,781

Output Variable	Value in 1000 USD
Assets	231,217
Liabilities	128,954
Expenses	106,324
Stockholders Equity	102,263
Net Income	-85,513
Comprehensive Net Income	-81,770
Economic Capital Ratio	-122%



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)